Benzinga | Apr 29, 2021 05:27PM EDT

Biomarin Pharmaceutical Sees FY 2021 Revs $1.75B-$1.85B Vs $1.81B Est

2021 Full-Year Financial Guidance (in millions, except %)

Item 2021 Guidance * (reaffirmed) Total Revenues $1,750 to $1,850 Vimizim Net Product Revenues $570 to $610 Kuvan Net Product Revenues $250 to $290 Naglazyme Net Product Revenues $365 to $395 Palynziq Net Product Revenues $210 to $250 Brineura Net Product Revenues $120 to $140

Cost of Sales (% of Total Revenues) 23% to 25% Research and Development Expense $645 to $695 Selling, General and Administrative Expense $725 to $775

GAAP Net Loss ($130) to ($80) Non-GAAP Income (1) $170 to $220